H1 launches new AI tool with 'power to be pharma's most impactful LLM'

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags AI Clinical trials Data management Artificial intelligence H1 Large language model

A new generative artificial intelligence (AI) tool has been launched by H1, a global healthcare data company and will have a 'profound impact on clinical trial diversity'.

Called GenoAI, the tool has been embedded in the company’s clinical trial intelligence platform, Trial Landscape and the company says it will analyze and respond to all types of complex inquiries.

The platform, H1 says, allows sponsors to identify new sites, centers of excellence, and investigators with diverse patients. It can evaluate site and PI patient recruitment strategies as well as gauge competition across trials.

GenosAI is described as a significant leap forward in enhancing efficiency, diversity, and innovation in the pharmaceutical industry.

According to advisory and consultancy company, Deloitte, AI has the potential to reduce drug discovery costs by as much as 70%. H1 says that GenosAI’s advanced data analysis capabilities can empower clinical researchers to make informed decisions more swiftly and accurately than ever before.

H1 says that with GenosAI clinical operations, feasibility, and medical teams can easily access deep insights, speed up workflows, explore new types of data, improve efficiencies and reduce costs, and accelerate time to market.

Profound impact on clinical trial diversity

Ariel Katz, CEO and co-founder, H1, said: “GenosAI has the power to be a pharma company’s most impactful Large Language Model (LLM) tool.

“With GenosAI, we’ve combined the power of conversational AI with our unmatched breadth of healthcare data to give sponsors access to the best data and technology possible. We hope this will have a profound impact on clinical trial diversity and efficacy.”

Trial Landscape contains a significant amount of underlying data available for clinical trials, pulling insights from more than 490,000 trials, 25 million publications, 10 million healthcare providers (including those with diversity data), 240 million patients, and 11 billion global claims.

Clients can also integrate their own data, such as historical trial performance and feasibility questionnaire responses. GenosAI pulls from this data and using the power of natural language processing (NLP), deciphers and responds to advanced analytical queries in a ChatGPT-like experience.

GenosAI sits on H1’s global data platform that uses state-of-the-art technologies ranging from machine learning (ML) to NLP to create a unified single source of truth for healthcare data. Data privacy and security is ensured through Microsoft Azure Enterprise GPT-4, Guardrails reduce hallucinations common in healthcare language models, and the Retrieval Augmented Generation (RAG) approach enriches the model with H1-specific data and knowledge. 

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us